What is Parion Sciences?
Parion Sciences is a development-stage biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies designed to restore the innate mucosal surface defense of the lung. Their scientific approach specifically targets respiratory diseases that stem from defective mucosal host defense mechanisms. The company is actively engaged in clinical trials, advancing a pipeline that includes promising candidates such as ENAC Pulmonary, tPAD, and various mucolytic agents. Parion Sciences aims to serve patients suffering from a range of respiratory conditions, including those with primary ciliary dyskinesia, by addressing the underlying biological defects.
How much funding has Parion Sciences raised?
Parion Sciences has raised a total of $3M across 1 funding round:
Grant
$3M
Grant (2014): $3M with participation from Cystic Fibrosis Foundation
Key Investors in Parion Sciences
Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation, based in Bethesda, Maryland, is a non-profit organization dedicated to finding a cure for cystic fibrosis and improving the lives of those affected by the disease.
What's next for Parion Sciences?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for Parion Sciences. This capital infusion is expected to accelerate the advancement of their clinical pipeline, potentially enabling further development and eventual commercialization of their therapeutic candidates. The company's focus on restoring innate lung defenses positions it to address significant unmet needs in the respiratory disease market, suggesting a trajectory aimed at scaling operations and expanding market reach.
See full Parion Sciences company page
